Inflammatory bowel disease (IBD)
Inflammatory bowel disease (IBD)
One in 200 Australians, including up to 10,000 children, suffer from inflammatory bowel disease (IBD) – an incurable painful and disruptive disease that often requires hospitalisation and surgery. In rare cases, it can be life threatening.
What is IBD?
IBD is an overarching term for a group of chronic intestinal conditions that cause inflammation in the digestive tract including the mouth, oesophagus, stomach and the small and large intestine.
The exact cause of IBD is unknown and there is no cure. Current treatment include drugs that suppress the immune system, but these become less effective over time and can have significant side effects including leaving patients with an increased risk of colorectal cancer and lymphoma.
IBD not only impacts health, but also social and emotional wellbeing. Having IBD can cause severe disruption to a patient’s life and the isolation and stress experienced can result in anxiety and depression.
Our Inflammatory bowel disease (IBD) research
Hudson Institute scientists are world-renowned specialists in the gut microbiome and are leading this game-changing area of research, including the discovery of more than 130 new gut bacteria. By combining their expertise in immunology, clinical disease and genomics they are discovering common protective and inflammation-causing gut bacteria in IBD patients and identifying treatments to target those bacteria.
Could the microbiome- revolutionise inflammatory bowel disease treatment?
New treatment or cure. Dr Sam Forster’s team has developed a new way of taking gut samples and looking at the bacteria within normal and damaged gut tissue. Importantly, they have discovered and are testing promising bacteria that could be used to treat, or even cure IBD.
The role of gut bacteria in immune response
Investigating the role of Interferon Epsilon in gut inflammation
The role of unconventional T cells in IBD
Understanding inflammation driven by bacterial infections and dysregulated host cell death
Understanding how loss of cell death regulators causes autoinflammation and chronic gut inflammation
Inflammatory bowel disease (IBD) news
State-of-the art genomic sequencer accelerates inflammation research
Rachel’s story | Living with Crohn’s disease
Crohn’s disease in Australia – the latest research
NHMRC Ideas Grants success
Crohn’s disease diagnosis impacts future health
Paving the way towards a new anti-inflammatory agent
NHMRC Ideas Grant success
NHMRC Fellowship success
See more news articles about Inflammatory bowel disease (IBD)
Inflammatory bowel disease (IBD) collaborators
- Monash Health
- Monash University
- Royal London Hospital
- Queen Mary University of London
- Massachusetts General Hospital for children
- Harvard Medical School
- Wellcome Trust Sanger Institute, Cambridge
- Walter and Eliza Hall Institute
- Institute for Molecular Bioscience, The University of Queensland
- Technische Universität München
- Imperial College London
- Peter Doherty Institute for Infection and Immunity
- Melbourne University
Support for people with Inflammatory bowel disease (IBD)
Hudson Institute scientists cannot provide medical advice.
Find out more about inflammatory bowel disease (IBD).
Keep up-to-date with our latest discoveries